 |
366 Diseases |  |
40 Trials |
|
40 Trials |  |
1659 News |  |
| «12345678910111213...2223» |
- || Torisel (temsirolimus) / Pfizer
Clinical, P1 data, Journal, Combination therapy: A phase I trial of the mTOR inhibitor temsirolimus in combination with capecitabine in patients with advanced malignancies. (Pubmed Central) - Jul 21, 2021
The combination of temsirolimus and capecitabine is safe on both a Q2-week and a Q3-week schedule. The combination demonstrated promising evidence of disease control in this highly refractory population and could be considered for testing in disease-specific phase II trials.
- |||| Revlimid (lenalidomide) / BMS, Torisel (temsirolimus) / Pfizer
Coming soon to @Haematologica: our phase I/II trial of temsirolimus and lenalidomide in relapsed lymphomas. Many thanks to my mentor @SoniSmithMD! #lymsm Preview of our work from ASH 2020: https://t.co/WaN1bYDzCL (Twitter) - Jul 20, 2021
- | perifosine (D21266) / AEterna Zentaris, Torisel (temsirolimus) / Pfizer
Trial completion, Trial completion date: Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma (clinicaltrials.gov) - Jul 19, 2021
P1/2, N=36, Completed, Sponsor: National Cancer Institute (NCI)
The combination demonstrated promising evidence of disease control in this highly refractory population and could be considered for testing in disease-specific phase II trials. Terminated --> Completed | Trial completion date: Oct 2015 --> Sep 2020
- || Votrient (pazopanib) / Novartis
Clinical, Journal: First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial. (Pubmed Central) - Jul 14, 2021
No treatment-related death occurred. Since pazopanib is active and well-tolerated in poor-risk patients with clear cell mRCC, our results support its use as first-line treatment in this setting.
- | Torisel (temsirolimus) / Pfizer
Enrollment open, Metastases: Hyper-Personalized Medicine Using Patient Derived Xenografts (PDXovo) for Metastatic Solid Tumors (clinicaltrials.gov) - Jul 1, 2021
P=N/A, N=50, Recruiting, Sponsor: Sunnybrook Health Sciences Centre
Since pazopanib is active and well-tolerated in poor-risk patients with clear cell mRCC, our results support its use as first-line treatment in this setting. Not yet recruiting --> Recruiting
- sirolimus / Generic mfg.
[VIRTUAL] THE ROLE OF AKT-ASSOCIATED SIGNALING PATHWAYS IN VOMITING EVOKED BY TARGETED CHEMOTHERAPEUTICS IN THE LEAST SHREW MODEL OF EMESIS () - Jun 29, 2021 - Abstract #MASCCISOO2021MASCC_ISOO_294;
Conclusions Our findings provide evidence of an emetic role for Akt inhibitors. We postulate that Akt protein inhibition causes over activity of its down- stream pro-emetic targets.
- || Torisel (temsirolimus) / Pfizer
Clinical, Journal: Comparison of three risk stratification models for non-clear cell renal cell carcinoma patients treated with temsirolimus as first-line therapy. (Pubmed Central) - Jun 28, 2021
All three prognostic models accurately predicted the survival of the non-clear cell RCC patients treated with temsirolimus as the first-line therapy. Furthermore, the ARCC risk model performed better than the other risk models in predicting survival.
- || Torisel (temsirolimus) / Pfizer
Clinical, P1 data, Journal: A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors. (Pubmed Central) - Jun 24, 2021
P1
Furthermore, the ARCC risk model performed better than the other risk models in predicting survival. The combination of temsirolimus and erlotinib at the RP2D was well tolerated, and the regimen resulted in prolonged disease stabilization in selected patients (NCT00770263).
- | Mekinist (trametinib) / Novartis, Torisel (temsirolimus) / Pfizer
Journal: The Combination of Trametinib, a MEK Inhibitor, and Temsirolimus, an mTOR Inhibitor, Radiosensitizes Lung Cancer Cells. (Pubmed Central) - Jun 22, 2021
The combination of temsirolimus and erlotinib at the RP2D was well tolerated, and the regimen resulted in prolonged disease stabilization in selected patients (NCT00770263). The combination of trametinib and temsirolimus can enhance lung cancer radiosensitivity in vitro and in vivo.
- || cixutumumab (IMC A12) / Eli Lilly, Torisel (temsirolimus) / Pfizer
P1 data, Journal: A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. (Pubmed Central) - Jun 16, 2021
Despite a strong scientific rationale for the combination, temsirolimus plus cixutumumab demonstrated limited antitumor activity and a greater than expected incidence of toxicity, including low-grade pneumonitis and hyperglycemia. Hence, the trial was stopped in favor of alternative androgen receptor/phosphatidylinositol 3-kinase-directed combinatorial therapies.
- | Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Preclinical, Journal: Comprehensive analysis of copy number variance and sensitivity to common targeted therapy in clear cell renal cell carcinoma: In silico analysis with in vitro validation. (Pubmed Central) - Jun 5, 2021
Here we show CNVs of several genes that are associated with sensitivity and resistance to commonly used TKIs and mTORi in ccRCC. Further validation and functional analyses are therefore needed.
- | omipalisib (GSK2126458) / GSK
Journal: The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis. (Pubmed Central) - Jun 3, 2021
Further validation and functional analyses are therefore needed. Based on our results, we conclude that GSK458 may serve as an attractive candidate to treat ovarian cancer.
- || Votrient (pazopanib) / Novartis, Torisel (temsirolimus) / Pfizer
Clinical, P2 data, Journal: Temsirolimus versus Pazopanib (TemPa) in Patients with Advanced Clear-cell Renal Cell Carcinoma and Poor-risk Features: A Randomized Phase II Trial. (Pubmed Central) - Jun 1, 2021
Based on our results, we conclude that GSK458 may serve as an attractive candidate to treat ovarian cancer. Temsirolimus and pazopanib had modest activity in patients with poor-risk clear-cell mRCC, and therefore their use should be discouraged in this setting.
- sirolimus / Generic mfg.
[VIRTUAL] Evidence for a nucleolar involvement in the effect of mTOR inhibitors on cell viability () - May 30, 2021 - Abstract #EACR2021EACR_2023;
Conclusion These results indicate that mTORC2 inhibition must be considered therapeutically, in agreement with the ongoing effort to translate those drugs into clinical practice. Importantly, these results agree with the notion that inhibition of nucleolar function is therapeutically useful and that the mTOR pathways offer possible targets to achieve such inhibition.
- sirolimus / Generic mfg.
[VIRTUAL] Evidence for a nucleolar involvement in the effect of mTOR inhibitors on cell viability () - May 30, 2021 - Abstract #EACR2021EACR_2022;
Conclusion These results indicate that mTORC2 inhibition must be considered therapeutically, in agreement with the ongoing effort to translate those drugs into clinical practice. Importantly, these results agree with the notion that inhibition of nucleolar function is therapeutically useful and that the mTOR pathways offer possible targets to achieve such inhibition.
- sirolimus / Generic mfg.
[VIRTUAL] Evidence for a nucleolar involvement in the effect of mTOR inhibitors on cell viability () - May 30, 2021 - Abstract #EACR2021EACR_2021;
Conclusion These results indicate that mTORC2 inhibition must be considered therapeutically, in agreement with the ongoing effort to translate those drugs into clinical practice. Importantly, these results agree with the notion that inhibition of nucleolar function is therapeutically useful and that the mTOR pathways offer possible targets to achieve such inhibition.
- sirolimus / Generic mfg.
[VIRTUAL] Evidence for a nucleolar involvement in the effect of mTOR inhibitors on cell viability () - May 30, 2021 - Abstract #EACR2021EACR_2020;
Conclusion These results indicate that mTORC2 inhibition must be considered therapeutically, in agreement with the ongoing effort to translate those drugs into clinical practice. Importantly, these results agree with the notion that inhibition of nucleolar function is therapeutically useful and that the mTOR pathways offer possible targets to achieve such inhibition.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] B7 immune checkpoint proteins as mediators of resistance to targeted therapy in renal cancer cells () - May 30, 2021 - Abstract #EACR2021EACR_1651;
Material and Methods In this study, we have analyzed the global expression of B7-family members (including PD-L1, PD-L2, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7) in renal cancer cells upon treatment with clinically relevant targeted therapies, including VEGF inhibitors (Axitinib, Cabozantinib, and Lenvatinib) and mTOR inhibitors (Everolimus and Temsirolimus)...Cell functional assays revealed the potential of specific B7 proteins to mediate intrinsic resistance to targeted therapy in renal cancer cells. Conclusion Our findings highlight novel B7 proteins as actionable immune checkpoint proteins in advanced and metastatic renal cancer cases resistant to current treatments.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] B7 immune checkpoint proteins as mediators of resistance to targeted therapy in renal cancer cells () - May 30, 2021 - Abstract #EACR2021EACR_1650;
Material and Methods In this study, we have analyzed the global expression of B7-family members (including PD-L1, PD-L2, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7) in renal cancer cells upon treatment with clinically relevant targeted therapies, including VEGF inhibitors (Axitinib, Cabozantinib, and Lenvatinib) and mTOR inhibitors (Everolimus and Temsirolimus)...Cell functional assays revealed the potential of specific B7 proteins to mediate intrinsic resistance to targeted therapy in renal cancer cells. Conclusion Our findings highlight novel B7 proteins as actionable immune checkpoint proteins in advanced and metastatic renal cancer cases resistant to current treatments.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] B7 immune checkpoint proteins as mediators of resistance to targeted therapy in renal cancer cells () - May 30, 2021 - Abstract #EACR2021EACR_1649;
Material and Methods In this study, we have analyzed the global expression of B7-family members (including PD-L1, PD-L2, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7) in renal cancer cells upon treatment with clinically relevant targeted therapies, including VEGF inhibitors (Axitinib, Cabozantinib, and Lenvatinib) and mTOR inhibitors (Everolimus and Temsirolimus)...Cell functional assays revealed the potential of specific B7 proteins to mediate intrinsic resistance to targeted therapy in renal cancer cells. Conclusion Our findings highlight novel B7 proteins as actionable immune checkpoint proteins in advanced and metastatic renal cancer cases resistant to current treatments.
- Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
[VIRTUAL] B7 immune checkpoint proteins as mediators of resistance to targeted therapy in renal cancer cells () - May 30, 2021 - Abstract #EACR2021EACR_1648;
Material and Methods In this study, we have analyzed the global expression of B7-family members (including PD-L1, PD-L2, B7-H2, B7-H3, B7-H4, B7-H5, B7-H6 and B7-H7) in renal cancer cells upon treatment with clinically relevant targeted therapies, including VEGF inhibitors (Axitinib, Cabozantinib, and Lenvatinib) and mTOR inhibitors (Everolimus and Temsirolimus)...Cell functional assays revealed the potential of specific B7 proteins to mediate intrinsic resistance to targeted therapy in renal cancer cells. Conclusion Our findings highlight novel B7 proteins as actionable immune checkpoint proteins in advanced and metastatic renal cancer cases resistant to current treatments.
- | Torisel (temsirolimus) / Pfizer
Trial primary completion date: Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma (clinicaltrials.gov) - May 28, 2021
P3, N=397, Recruiting, Sponsor: National Cancer Institute (NCI)
Conclusion Our findings highlight novel B7 proteins as actionable immune checkpoint proteins in advanced and metastatic renal cancer cases resistant to current treatments. Trial primary completion date: Jun 2025 --> Dec 2024
- || Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Review, Journal: Metastatic nonclear renal cell carcinoma current review in evolving treatment strategies. (Pubmed Central) - May 26, 2021
Trial primary completion date: Jun 2025 --> Dec 2024 Here, we report currently available data about biology and treatment of nonclear cell RCC.
- Revlimid (lenalidomide) / BMS
[VIRTUAL] High-risk Mantle Cell Lymphoma in the LyMa Trial: a LYSA Study. () - May 22, 2021 - Abstract #ICML2021ICML_376;
Known risk factors do not perfectly identify high-risk MCL patients at baseline. High-risk patients with early disease progression had an extremely dismal prognosis and should receive innovative strategies combined with systematic CNS prophylaxis as salvage therapy.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Clinical, P2 data, Journal: A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. (Pubmed Central) - May 21, 2021
However, TC induced responses in cetuximab-refractory patients with good tolerability. The post hoc observation of activity in patients with acquired resistance (after prior benefit from cetuximab monotherapy) may warrant further investigation.
- ||| Torisel (temsirolimus) / Pfizer
Temsirolimus Injection Now Available from Fresenius Kabi https://t.co/tkD1ECAU8U (Twitter) - May 21, 2021
- Torisel (temsirolimus) / Pfizer
[VIRTUAL] Life-supporting Multi-gene Cardiac Xenografts From Swine Demonstrate Survival >8 Months and Preclinical Efficacy for Human Clinical Trials () - May 18, 2021 - Abstract #ATC2021ATC_2234;
Xenografts with multiple transgenes and knockouts produce durable long-term survival and demonstrate pre-clinical efficacy to pursue the first human clinical trials. Consideration should be those with CMAHKO and GHRKO.
- | Avastin (bevacizumab) / Roche, Opdivo (nivolumab) / Ono Pharma, BMS, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Journal: Interdisciplinary recommendations for the treatment of advanced metastatic renal cell carcinoma (Pubmed Central) - May 15, 2021
The use of both the combination of nivolumab + ipilimumab and cabozantinib is restricted to intermediate and high-risk patients...Temsirolimus is only approved for high-risk patients.Sunitinib and pazopanib can also be applied as second-line options - for pazopanib the use is restricted to the event of cytokine failure...Furthermore, the combination of lenvatinib + everolimus and axitinib are approved treatment options in the second-line and further settings...As in previous years, the experts intended to provide recommendations for clinical practice. The results are presented in this publication.
- Revlimid (lenalidomide) / BMS
[VIRTUAL] HIGH-RISK MANTLE CELL LYMPHOMA IN THE LYMA TRIAL: A LYSA STUDY. () - May 13, 2021 - Abstract #EHA2021EHA_1439;
P3
Salvage therapies consisted of chemotherapy in 26 patients (CHOP, MTX-AraC, bendamustine, VR-CAP), rituximab in 26, temsirolimus in five, lenalidomide and combination of ibrutinib and lenalidomide in two other patients, as second line therapy...Conclusion Known risk factors do not perfectly identify high-risk MCL patients at baseline. High-risk patients with early disease progression had an extremely dismal prognosis and should receive innovative strategies combined with systematic CNS prophylaxis as salvage therapy.
- || Torisel (temsirolimus) / Pfizer
Clinical, Journal: Raptor and rictor expression in patients with human papillomavirus-related oropharyngeal squamous cell carcinoma. (Pubmed Central) - May 12, 2021
These results suggest that raptor and rictor have important roles in HPV-related OPSCC and that temsirolimus is a potential therapeutic agent for patients with HPV-related OPSCC. This is the first report to reveal the overexpression of raptor and rictor in HPV-related OPSCC.
- Xeljanz (tofacitinib) / Pfizer
[VIRTUAL] Uncoupling of T-cell bispecific antibody-induced cytokine release and cytotoxicity revealed by differential activities of mTOR, JAK1/2 and Src inhibitors. (eTalks Room) - May 11, 2021 - Abstract #CIMT2021CIMT_147;
The Src inhibitor dasatinib could rather stand as a potential antidote for on-target off-tumor activity or high-grade CRS. The data are being validated in vivo.
- | Torisel (temsirolimus) / Pfizer, Rituxan (rituximab) / Roche
Enrollment change, Trial termination: Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma (clinicaltrials.gov) - May 5, 2021
P2, N=9, Terminated, Sponsor: National Cancer Institute (NCI)
The data are being validated in vivo. N=144 --> 9 | Active, not recruiting --> Terminated
- Torisel (temsirolimus) / Pfizer
[VIRTUAL] Protective and beneficial effects of temsirolimus on human chondrocyte under interleukin 1-beta stimulation () - May 3, 2021 - Abstract #OARSI2021OARSI_183;
However, effects of temsirolimus against OA have not yet been examined. Therefore, the purpose of this study was to evaluate the effect of temsirolimus on interleukin (IL) 1beta-induced responses and changes in human chondrocytes.
- Avastin (bevacizumab) / Roche, Mustargen (mechlorethamine) / Recordati
[VIRTUAL] High-grade glioma of central nervous system: Single center treatment experience. () - Apr 29, 2021 - Abstract #ASCO2021ASCO_3900;
Despite radiotherapy and chemotherapy, prognosis is very poor . The progression free and overall survival rates of patients were similar to literature .
- | Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Trial completion date, Trial primary completion date, Metastases: Phase II Study of Alternating Sunitinib and Temsirolimus (clinicaltrials.gov) - Apr 29, 2021
P2, N=37, Active, not recruiting, Sponsor: Dartmouth-Hitchcock Medical Center
The progression free and overall survival rates of patients were similar to literature . Trial completion date: Jun 2021 --> Dec 2021 | Trial primary completion date: Feb 2021 --> Dec 2021
- sapanisertib (TAK-228) / Takeda, serabelisib (MLN1117) / Takeda, Petra Pharma
[VIRTUAL] Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer. () - Apr 28, 2021 - Abstract #ASCO2021ASCO_2185;
P1
There were few serious adverse events, and most side effects were managed with routine supportive care interventions . Preliminary clinical results appear very promising, especially for patients with PI3K/AKT/mTOR pathway mutations .
- | cisplatin / Generic mfg., sirolimus / Generic mfg.
Journal, Cancer stem cells: mTOR Inhibition Ablates Cisplatin-Resistant Salivary Gland Cancer Stem Cells. (Pubmed Central) - Apr 24, 2021
Viability assays determined the effect of several inhibitors of PI3k/mTOR signaling (e.g., temsirolimus, BKM120, AZD8055, PF4708671) and/or cisplatin on survival of human MEC cells...Remarkably, temsirolimus slowed down tumor growth and decreased the fraction of CSCs (P < 0.05) even in presence of cisplatin in a short-term in vivo experiment. Collectively, these results demonstrate that therapeutic inhibition of mTOR ablates cytotoxic-resistant CSCs, and they suggest that a combination of an mTOR inhibitor and platinum-based chemotherapy might be beneficial to patients with salivary gland mucoepidermoid carcinoma.
- || Recentin (cediranib) / AstraZeneca, Torisel (temsirolimus) / Pfizer
Trial completion, Enrollment change, Trial completion date, Metastases: AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies (clinicaltrials.gov) - Apr 21, 2021
P1, N=11, Completed, Sponsor: Susana M. Campos, MD
Collectively, these results demonstrate that therapeutic inhibition of mTOR ablates cytotoxic-resistant CSCs, and they suggest that a combination of an mTOR inhibitor and platinum-based chemotherapy might be beneficial to patients with salivary gland mucoepidermoid carcinoma. Active, not recruiting --> Completed | N=50 --> 11 | Trial completion date: Apr 2020 --> Mar 2021
- ||| Torisel (temsirolimus) / Pfizer
Clinical: Nope, had explosive disease with rapid clinical decline. Was back to yard work within 2-3 weeks of torisel. (Twitter) - Apr 20, 2021
- ||| Votrient (pazopanib) / Novartis, Torisel (temsirolimus) / Pfizer
Clinical: I think I had a patient with a decent response to pazopanib after failure of afinitor or torisel... interesting about exemestane! (Twitter) - Apr 20, 2021
- || Torisel (temsirolimus) / Pfizer
Ideas for treating malignant PEcoma after progression on temsirolimus? I see data for adding exemestane. Other ideas? TSC2 mutant+. Had very nice response lasting 4months @breelynwilkyMD @JTrentMDPhD @bvantine1 @immunosarc @VivekSubbiah (Twitter) - Apr 20, 2021
- || perifosine (D21266) / AEterna Zentaris, Torisel (temsirolimus) / Pfizer
Clinical, P1 data, Journal: Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. (Pubmed Central) - Apr 20, 2021
Active, not recruiting --> Completed | N=50 --> 11 | Trial completion date: Apr 2020 --> Mar 2021 Combining the mTOR inhibitor temsirolimus dosed at 115 mg weekly and the AKT inhibitor perifosine dosed at 100 mg daily (following 600 mg load) is tolerable in heavily pretreated adults with recurrent MGs.
- | Sutent (sunitinib) / Pfizer
Preclinical, Journal, Pleural effusion: Novel Patient Metastatic Pleural Effusion-Derived Xenograft Model of Renal Medullary Carcinoma Demonstrates Therapeutic Efficacy of Sunitinib. (Pubmed Central) - Apr 13, 2021
Using the PE PDX model, sunitinib demonstrated therapeutic efficacy for RMC. This model can serve as a foundation for future mechanistic and therapeutic studies for primary and metastatic RMC.
- || Torisel (temsirolimus) / Pfizer
Review, Journal: PI3K/AKT/mTOR signalling pathway involvement in renal cell carcinoma pathogenesis (Review). (Pubmed Central) - Apr 7, 2021
Temsirolimus and everolimus are two mTOR inhibitors that are currently used for the treatment of RCC. Drugs targeting the PI3K/AKT/mTOR signalling pathway may be one of the best therapeutic options for RCC.
- ||| Opdivo (nivolumab) / Ono Pharma, BMS
Clinical, Journal, Adverse events: Frequency of pre-treatment may not increase the immune-related adverse events of RCC patients treated with nivolumab. (Pubmed Central) - Apr 1, 2021
No statistically significant relations were found between grade of irAE and numbers of treatments prior to nivolumab. Patients treated with nivolumab should be closely monitored for irAE regardless number of previous therapies.
- || Torisel (temsirolimus) / Pfizer, Unituxin (dinutuximab) / United Therapeutics Corp, Ohara Pharma
Enrollment closed: Irinotecan Hydrochloride and Temozolomide With Temsirolimus or Dinutuximab in Treating Younger Patients With Refractory or Relapsed Neuroblastoma (clinicaltrials.gov) - Mar 30, 2021
P2, N=73, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Patients treated with nivolumab should be closely monitored for irAE regardless number of previous therapies. Completed --> Active, not recruiting
- |||| Inlyta (axitinib) / Pfizer, Torisel (temsirolimus) / Pfizer
Clinical: That is great. We did clinical trials @VUMChealth between ‘09-‘14. When he first started there were only 2 approved RCC drugs available! I like to think Don’s trials of Avaston, Inlyta, Afinitor & Torisel made a difference in somone’s else’s survival. #hope (Twitter) - Mar 20, 2021
- || Inlyta (axitinib) / Pfizer, Torisel (temsirolimus) / Pfizer, Sutent (sunitinib) / Pfizer
Clinical, Journal: Long-term disease control of metastatic type 2 papillary renal cell carcinoma using local treatment and molecular targeted therapy: A case report. (Pubmed Central) - Mar 19, 2021
The patient died 80 months after the initial recurrence. Using multidisciplinary treatment, durable disease control was achieved in a patient with metastatic type 2 PRCC.
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
[VIRTUAL] Falcon-X 3D in vitro tumor model platform for screening patient-derived NSCLC, CRC, and RCC tumors with targeted therapy and immunotherapy () - Mar 13, 2021 - Abstract #AACR2021AACR_4204;
For CRC PDX tumors, Oxaliplatin, Cetuximab, 5-FU, Bevacizumab (anti-VEGF), and Pembrolizumab (anti-PD1) were assayed; for RCC: Sunitinib, Pazopanib, Temsirolimus, Bevacizumab, and Pembrolizumab; for NSCLC: Docetaxel, Cisplatin, Afatinib, Atezolizumab (anti-PDL1), and Pembrolizumab...Such a platform is potentially suitable for cancer drug discovery and clinical decision making for screening cancer therapeutic efficacy. Further studies include identifying cytokines that modulate the immune response to fibroblast co-culture, expanding the approach to other solid tumor types such as breast, brain, sarcoma, and melanoma, as well as screening novel immunotherapy agents.
- Torisel (temsirolimus) / Pfizer
[VIRTUAL] mTOR inhibitor induces non-apoptotic, autophagy dependent cell death (ADCD) in TP53 mutant HNSCC () - Mar 11, 2021 - Abstract #AACR2021AACR_2878;
We investigated the mechanism by which the mTOR inhibitor CCI-779 inhibits cell growth of TP53 mutant HNSCC in vitro...This is a novel mechanism of how rapalogues induce ADCD through the stabilization/ activation of ULK1 in HPV-negative TP53 mutant HNSCC cells. Together these data highlight the importance of how mTORi can be used to accelerate tumor cell death in HPV-negative TP53 mutant HNSCC.